AACE Clinical Case Reports最新文献

英文中文

Alpelisib-Induced Diabetic Ketoacidosis and Insulin-Resistant Hyperglycemia

Q3 Medicine

AACE Clinical Case Reports

Pub Date : 2025-01-01 DOI: 10.1016/j.aace.2024.10.002

Michael Loke DO , Vishal Sehgal MD , Niraj Gupta MD

Background/Objective

Alpelisib is a phosphatidylinositol 3-kinase inhibitor used to treat certain hormone therapy resistant breast cancers that can cause hyperglycemia through inhibition of the insulin signaling cascade. Diabetic ketoacidosis with the initiation of alpelisib remains a rare complication. The objective of this report is to describe a patient with alpelisib-induced diabetic ketoacidosis and the difficulties of management.

Case Report

A 59-year-old woman was admitted to the hospital with a history of noninsulin dependent type 2 diabetes on metformin presented with diabetic ketoacidosis. One month prior to this hospitalization, the patient was started on alpelisib. On presentation, blood glucose level was 612 mg/dL and hemoglobin A1c level was 11.9% (107 mmol/mol), a 4.6% (27 mmol/mol) increase from 2 months prior. The patient was started on intravenous insulin and alpelisib was held resulting in rapid resolution of the patient’s hyperglycemia and ketoacidosis. However, with reinitiation of alpelisib the patient developed worsening hyperglycemia. Relative glycemic control was ultimately obtained with 3 oral agents and high doses of insulin.

Discussion

Direct inhibition of insulin signaling by alpelisib leads to insulin-resistant hyperglycemia. Most cases can be controlled with oral agents; however, insulin therapy is required in rare instances. Although more effective for glycemic control, insulin therapy has the potential to decrease the antitumor effects of alpelisib.

Conclusion

Diabetic ketoacidosis is a rare complication of alpelisib initiation, which is quickly resolved with cessation of the agent. For patients where cessation is not an option, insulin and insulin sensitizing agents can be used to achieve glycemic control at the potential detriment of tumor treatment.

{"title":"Alpelisib-Induced Diabetic Ketoacidosis and Insulin-Resistant Hyperglycemia","authors":"Michael Loke DO , Vishal Sehgal MD , Niraj Gupta MD","doi":"10.1016/j.aace.2024.10.002","DOIUrl":"10.1016/j.aace.2024.10.002","url":null,"abstract":"<div><h3>Background/Objective</h3><div>Alpelisib is a phosphatidylinositol 3-kinase inhibitor used to treat certain hormone therapy resistant breast cancers that can cause hyperglycemia through inhibition of the insulin signaling cascade. Diabetic ketoacidosis with the initiation of alpelisib remains a rare complication. The objective of this report is to describe a patient with alpelisib-induced diabetic ketoacidosis and the difficulties of management.</div></div><div><h3>Case Report</h3><div>A 59-year-old woman was admitted to the hospital with a history of noninsulin dependent type 2 diabetes on metformin presented with diabetic ketoacidosis. One month prior to this hospitalization, the patient was started on alpelisib. On presentation, blood glucose level was 612 mg/dL and hemoglobin A1c level was 11.9% (107 mmol/mol), a 4.6% (27 mmol/mol) increase from 2 months prior. The patient was started on intravenous insulin and alpelisib was held resulting in rapid resolution of the patient’s hyperglycemia and ketoacidosis. However, with reinitiation of alpelisib the patient developed worsening hyperglycemia. Relative glycemic control was ultimately obtained with 3 oral agents and high doses of insulin.</div></div><div><h3>Discussion</h3><div>Direct inhibition of insulin signaling by alpelisib leads to insulin-resistant hyperglycemia. Most cases can be controlled with oral agents; however, insulin therapy is required in rare instances. Although more effective for glycemic control, insulin therapy has the potential to decrease the antitumor effects of alpelisib.</div></div><div><h3>Conclusion</h3><div>Diabetic ketoacidosis is a rare complication of alpelisib initiation, which is quickly resolved with cessation of the agent. For patients where cessation is not an option, insulin and insulin sensitizing agents can be used to achieve glycemic control at the potential detriment of tumor treatment.</div></div>","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"11 1","pages":"Pages 40-44"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Euglycemic Diabetic Ketoacidosis in a Pregnant Patient on Insulin Pump Therapy

Q3 Medicine

AACE Clinical Case Reports

Pub Date : 2025-01-01 DOI: 10.1016/j.aace.2024.10.004

Hesham Yasin MD , Jordan D. Ross MD , James Turner MD , Samuel Dagogo-Jack MD, DSc

Background/Objective

Diabetic ketoacidosis is a common endocrine emergency. A subset of patients present with euglycemic diabetic ketoacidosis, which may be diagnosed late due to its rarity and relatively lower blood glucose levels. Pregnancy is associated with euglycemic diabetic ketoacidosis, which can lead to maternal and fetal demise without prompt treatment. The objective of this case report is to describe a patient with type 1 diabetes mellitus who developed euglycemic diabetic ketoacidosis on insulin pump therapy during pregnancy.

Case Report

A 30-year-old pregnant patient at 33 weeks of gestation with type 1 diabetes mellitus on continuous subcutaneous insulin infusion presented to the emergency department with vomiting. Her serum bicarbonate of 9 mmol/L was accompanied by serum glucose of 130 mg/dL, moderate blood ketones, and urine ketones 80 mg/dL (large). She was treated with intravenous insulin infusion without complications to herself or the fetus.

Discussion

Pregnancy is a common background for euglycemic diabetic ketoacidosis and can lead to maternal and fetal demise if not addressed early. Despite insulin resistance in pregnancy, a relatively low blood glucose is maintained by increased glycogen storage and increased fetoplacental uptake. Altered acid-base physiology in pregnancy may also increase the propensity for euglycemic diabetic ketoacidosis.

Conclusion

Diabetic ketoacidosis can present in pregnancy with euglycemia, and a high index of suspicion is needed by both patients and health care teams. There are a few reports on this phenomenon in a pregnant patient using an insulin pump. Early identification and treatment are important to prevent maternal and fetal complications.

{"title":"Euglycemic Diabetic Ketoacidosis in a Pregnant Patient on Insulin Pump Therapy","authors":"Hesham Yasin MD , Jordan D. Ross MD , James Turner MD , Samuel Dagogo-Jack MD, DSc","doi":"10.1016/j.aace.2024.10.004","DOIUrl":"10.1016/j.aace.2024.10.004","url":null,"abstract":"<div><h3>Background/Objective</h3><div>Diabetic ketoacidosis is a common endocrine emergency. A subset of patients present with euglycemic diabetic ketoacidosis, which may be diagnosed late due to its rarity and relatively lower blood glucose levels. Pregnancy is associated with euglycemic diabetic ketoacidosis, which can lead to maternal and fetal demise without prompt treatment. The objective of this case report is to describe a patient with type 1 diabetes mellitus who developed euglycemic diabetic ketoacidosis on insulin pump therapy during pregnancy.</div></div><div><h3>Case Report</h3><div>A 30-year-old pregnant patient at 33 weeks of gestation with type 1 diabetes mellitus on continuous subcutaneous insulin infusion presented to the emergency department with vomiting. Her serum bicarbonate of 9 mmol/L was accompanied by serum glucose of 130 mg/dL, moderate blood ketones, and urine ketones 80 mg/dL (large). She was treated with intravenous insulin infusion without complications to herself or the fetus.</div></div><div><h3>Discussion</h3><div>Pregnancy is a common background for euglycemic diabetic ketoacidosis and can lead to maternal and fetal demise if not addressed early. Despite insulin resistance in pregnancy, a relatively low blood glucose is maintained by increased glycogen storage and increased fetoplacental uptake. Altered acid-base physiology in pregnancy may also increase the propensity for euglycemic diabetic ketoacidosis.</div></div><div><h3>Conclusion</h3><div>Diabetic ketoacidosis can present in pregnancy with euglycemia, and a high index of suspicion is needed by both patients and health care teams. There are a few reports on this phenomenon in a pregnant patient using an insulin pump. Early identification and treatment are important to prevent maternal and fetal complications.</div></div>","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"11 1","pages":"Pages 49-52"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Uremic Leontiasis Ossea due to Resistant Secondary Hyperparathyroidism

Q3 Medicine

AACE Clinical Case Reports

Pub Date : 2025-01-01 DOI: 10.1016/j.aace.2024.09.001

Kubra Tuna MD , Olesya Ilkun MD, PhD , Peter T. Dziegielewski MD , Anu Sharma MD

Background/Objective

Severe progressive overgrowth of the facial bones known as uremic leontiasis ossea (ULO) is a rare complication of resistant hyperparathyroidism in end-stage renal disease (ESRD). The objective of this report is to describe the presentation and treatment of ULO.

Case Report

A 48-year-old woman with a history of hypertension, coronary artery disease, and ESRD on hemodialysis presented with severe secondary hyperparathyroidism and calciphylaxis. She had significant changes to her face in the last 3 months leading to oropharyngeal dysphagia and difficulty articulating. Physical examination revealed bony overgrowth in her upper jaw and hard palate, widely spaced teeth, and calcinosis cutis. Her parathyroid hormone (PTH), calcium, and phosphorus levels were 5066 pg/mL (normal range, 12-88 pg/mL); 10.0 mg/dL (8.4-10.2 mg/dL); and 5.4 mg/dL (2.7-4.5 mg/dL); respectively. Using a multidisciplinary approach, she successfully underwent a 3.5-gland parathyroidectomy (immediate postoperative PTH level, 600 pg/mL). She was discharged without complication. Pathology showed hypercellular parathyroid glands with reactive changes.

Discussion

ULO, the most severe form of renal osteodystrophy, results in hypertrophy of the craniofacial skeleton. It carries the risk of significant comorbidities due to cranial nerve compression, respiratory compromise, dysarthria, and dysphagia.

Conclusion

With prolonged, uncontrolled PTH stimulation in ESRD, significant facial disfiguration with disabilities can occur. It is of utmost importance to adhere to guideline-specified PTH targets in persons with ESRD to prevent patient harm from permanent physical deformities.

{"title":"Uremic Leontiasis Ossea due to Resistant Secondary Hyperparathyroidism","authors":"Kubra Tuna MD , Olesya Ilkun MD, PhD , Peter T. Dziegielewski MD , Anu Sharma MD","doi":"10.1016/j.aace.2024.09.001","DOIUrl":"10.1016/j.aace.2024.09.001","url":null,"abstract":"<div><h3>Background/Objective</h3><div>Severe progressive overgrowth of the facial bones known as uremic leontiasis ossea (ULO) is a rare complication of resistant hyperparathyroidism in end-stage renal disease (ESRD). The objective of this report is to describe the presentation and treatment of ULO.</div></div><div><h3>Case Report</h3><div>A 48-year-old woman with a history of hypertension, coronary artery disease, and ESRD on hemodialysis presented with severe secondary hyperparathyroidism and calciphylaxis. She had significant changes to her face in the last 3 months leading to oropharyngeal dysphagia and difficulty articulating. Physical examination revealed bony overgrowth in her upper jaw and hard palate, widely spaced teeth, and calcinosis cutis. Her parathyroid hormone (PTH), calcium, and phosphorus levels were 5066 pg/mL (normal range, 12-88 pg/mL); 10.0 mg/dL (8.4-10.2 mg/dL); and 5.4 mg/dL (2.7-4.5 mg/dL); respectively. Using a multidisciplinary approach, she successfully underwent a 3.5-gland parathyroidectomy (immediate postoperative PTH level, 600 pg/mL). She was discharged without complication. Pathology showed hypercellular parathyroid glands with reactive changes.</div></div><div><h3>Discussion</h3><div>ULO, the most severe form of renal osteodystrophy, results in hypertrophy of the craniofacial skeleton. It carries the risk of significant comorbidities due to cranial nerve compression, respiratory compromise, dysarthria, and dysphagia.</div></div><div><h3>Conclusion</h3><div>With prolonged, uncontrolled PTH stimulation in ESRD, significant facial disfiguration with disabilities can occur. It is of utmost importance to adhere to guideline-specified PTH targets in persons with ESRD to prevent patient harm from permanent physical deformities.</div></div>","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"11 1","pages":"Pages 5-9"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bilateral Adrenal Tumors: A Visual Case Series

Q3 Medicine

AACE Clinical Case Reports

Pub Date : 2025-01-01 DOI: 10.1016/j.aace.2024.11.006

Dipika R. Mohan MD, PhD , Rutu Shah MD , Malak Itani MD , Mohamed Awali MD , Sina Jasim MD, MPH

引用次数: 0

Digital Twin Technology in Resolving Polycystic Ovary Syndrome and Improving Metabolic Health: A Comprehensive Case Study

Q3 Medicine

AACE Clinical Case Reports

Pub Date : 2025-01-01 DOI: 10.1016/j.aace.2024.11.004

Paramesh Shamanna MD , Anuj Maheshwari MD , Ashok Keshavamurthy MD , Sanjay Bhat DM , Abhijit Kulkarni DM , Shivakumar R MD , Kumar K MD , Mukulesh Gupta MD , Mohamed Thajudeen MD , Ranjita Kulkarni MD , Shashikiran Patil MD , Shashank Joshi DM

Background

Clinical manifestations of polycystic ovary syndrome (PCOS) are heterogeneous, with hallmarks including anovulation, androgen excess, and insulin resistance.

Case Report

A 38-year-old female with typical PCOS features presented with hypertension, obesity, and elevated fasting and postprandial insulin levels. She was enrolled in the Digital Twin (DT) platform, which uses artificial intelligence and Internet of Things to deliver personalized nutrition by predicting postprandial glucose responses and suggesting alternative foods with lower postprandial glucose response through a mobile app. After 360 days, significant improvements were observed. Weight decreased from 65.4 kg to 57.3 kg (−12.4%); body mass index lowered from 26.2 to 22.96 (−12.4%); Waist circumference reduced from 104 cm to 86.3 cm (−17.0%); clinic systolic blood pressure/diastolic blood pressure reduced from 144/93 to 102/80 mmHg (−29.17%/-13.98%); fasting insulin dropped from 27.6 to 15.5 μIU/mL (−43.8%); postprandial insulin decreased from 182.4 to 23.8 μIU/mL (−87.0%); Homeostatic Model Assessment of Insulin Resistance reduced from 6.47 to 3.48 (−46.2%); estimated glomerular filteration rate improved from 116 to 128 mL/min/1.73m2 (+10.3%); urine microalbumin creatinine ratio decreased from 596 to 73 mg/g (−87.8%). Ultrasound showed reduced ovarian volume and improved fatty liver infiltration, while computed tomography scan revealed significant reductions in epicardial (21.8%), pericardial (69.9%), and visceral fat (44.4%).

Discussion

This case shows the effective use of DT technology for managing PCOS, significantly improving weight, body mass index, insulin, blood pressure, and lipid profile. It supports the potential of artificial intelligence-driven, personalized interventions in chronic disease management.

Conclusion

This case highlights the potential of DT technology in managing PCOS, showing significant metabolic and reproductive improvements, suggesting promising future research directions.

{"title":"Digital Twin Technology in Resolving Polycystic Ovary Syndrome and Improving Metabolic Health: A Comprehensive Case Study","authors":"Paramesh Shamanna MD , Anuj Maheshwari MD , Ashok Keshavamurthy MD , Sanjay Bhat DM , Abhijit Kulkarni DM , Shivakumar R MD , Kumar K MD , Mukulesh Gupta MD , Mohamed Thajudeen MD , Ranjita Kulkarni MD , Shashikiran Patil MD , Shashank Joshi DM","doi":"10.1016/j.aace.2024.11.004","DOIUrl":"10.1016/j.aace.2024.11.004","url":null,"abstract":"<div><h3>Background</h3><div>Clinical manifestations of polycystic ovary syndrome (PCOS) are heterogeneous, with hallmarks including anovulation, androgen excess, and insulin resistance.</div></div><div><h3>Case Report</h3><div>A 38-year-old female with typical PCOS features presented with hypertension, obesity, and elevated fasting and postprandial insulin levels. She was enrolled in the Digital Twin (DT) platform, which uses artificial intelligence and Internet of Things to deliver personalized nutrition by predicting postprandial glucose responses and suggesting alternative foods with lower postprandial glucose response through a mobile app. After 360 days, significant improvements were observed. Weight decreased from 65.4 kg to 57.3 kg (−12.4%); body mass index lowered from 26.2 to 22.96 (−12.4%); Waist circumference reduced from 104 cm to 86.3 cm (−17.0%); clinic systolic blood pressure/diastolic blood pressure reduced from 144/93 to 102/80 mmHg (−29.17%/-13.98%); fasting insulin dropped from 27.6 to 15.5 μIU/mL (−43.8%); postprandial insulin decreased from 182.4 to 23.8 μIU/mL (−87.0%); Homeostatic Model Assessment of Insulin Resistance reduced from 6.47 to 3.48 (−46.2%); estimated glomerular filteration rate improved from 116 to 128 mL/min/1.73m2 (+10.3%); urine microalbumin creatinine ratio decreased from 596 to 73 mg/g (−87.8%). Ultrasound showed reduced ovarian volume and improved fatty liver infiltration, while computed tomography scan revealed significant reductions in epicardial (21.8%), pericardial (69.9%), and visceral fat (44.4%).</div></div><div><h3>Discussion</h3><div>This case shows the effective use of DT technology for managing PCOS, significantly improving weight, body mass index, insulin, blood pressure, and lipid profile. It supports the potential of artificial intelligence-driven, personalized interventions in chronic disease management.</div></div><div><h3>Conclusion</h3><div>This case highlights the potential of DT technology in managing PCOS, showing significant metabolic and reproductive improvements, suggesting promising future research directions.</div></div>","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"11 1","pages":"Pages 70-74"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Case of Severe Cushing Syndrome due to Metastatic Adrenocortical Carcinoma Treated With Osilodrostat

Q3 Medicine

AACE Clinical Case Reports

Pub Date : 2025-01-01 DOI: 10.1016/j.aace.2024.10.005

Kathleen R. Ruddiman DO , Catherine E. Price MD, ECNU, FACE , Alexander K. Bonnecaze MD

Background/Objective

Osilodrostat used with block-and-replace dosing regimen is an off-label alternative to traditional management of Cushing syndrome due to adrenocortical carcinoma (ACC).

Case Report

A 70-year-old woman presented with abdominal pain and was found to have a large right adrenal mass and hypercortisolism. Right adrenalectomy was pursued with pathology consistent with diagnosis of ACC. Three months after surgery, hypercortisolemia recurred and bony metastatic disease was detected soon after. The patient received chemotherapy and mitotane; however, mitotane was stopped after development of hemolytic anemia. The patient’s urinary free cortisol became severely elevated, and osilodrostat was subsequently initiated for steroidogenesis inhibition. As dosage was increased, the patient presented with fatigue and hypotension and was diagnosed with adrenal insufficiency. This was managed with hydrocortisone in a block-and-replace dosing strategy.

Discussion

ACC can cause severe hypercortisolism, which is associated with significant morbidity and mortality. Osilodrostat was an effective off-label option for steroidogenesis inhibition in our patient who developed severe hypercortisolism and did not tolerate first-line therapy. Our patient also experienced iatrogenic adrenal insufficiency during treatment with osilodrostat, which was successfully managed using a block-and-replace strategy. There are limited cases currently available that document use of osilodrostat under the above circumstances.

Conclusion

Although osilodrostat is currently only approved for use in pituitary Cushing disease, we found it effective in off-label use to treat Cushing syndrome due to ACC. Using a block-and-replace treatment strategy was a practical intervention after development of adrenal insufficiency.

{"title":"A Case of Severe Cushing Syndrome due to Metastatic Adrenocortical Carcinoma Treated With Osilodrostat","authors":"Kathleen R. Ruddiman DO , Catherine E. Price MD, ECNU, FACE , Alexander K. Bonnecaze MD","doi":"10.1016/j.aace.2024.10.005","DOIUrl":"10.1016/j.aace.2024.10.005","url":null,"abstract":"<div><h3>Background/Objective</h3><div>Osilodrostat used with block-and-replace dosing regimen is an off-label alternative to traditional management of Cushing syndrome due to adrenocortical carcinoma (ACC).</div></div><div><h3>Case Report</h3><div>A 70-year-old woman presented with abdominal pain and was found to have a large right adrenal mass and hypercortisolism. Right adrenalectomy was pursued with pathology consistent with diagnosis of ACC. Three months after surgery, hypercortisolemia recurred and bony metastatic disease was detected soon after. The patient received chemotherapy and mitotane; however, mitotane was stopped after development of hemolytic anemia. The patient’s urinary free cortisol became severely elevated, and osilodrostat was subsequently initiated for steroidogenesis inhibition. As dosage was increased, the patient presented with fatigue and hypotension and was diagnosed with adrenal insufficiency. This was managed with hydrocortisone in a block-and-replace dosing strategy.</div></div><div><h3>Discussion</h3><div>ACC can cause severe hypercortisolism, which is associated with significant morbidity and mortality. Osilodrostat was an effective off-label option for steroidogenesis inhibition in our patient who developed severe hypercortisolism and did not tolerate first-line therapy. Our patient also experienced iatrogenic adrenal insufficiency during treatment with osilodrostat, which was successfully managed using a block-and-replace strategy. There are limited cases currently available that document use of osilodrostat under the above circumstances.</div></div><div><h3>Conclusion</h3><div>Although osilodrostat is currently only approved for use in pituitary Cushing disease, we found it effective in off-label use to treat Cushing syndrome due to ACC. Using a block-and-replace treatment strategy was a practical intervention after development of adrenal insufficiency.</div></div>","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"11 1","pages":"Pages 53-57"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Rare Case of Thyrotoxic Periodic Paralysis in a Patient With Concomitant Methimazole-Induced Agranulocytosis

Q3 Medicine

AACE Clinical Case Reports

Pub Date : 2025-01-01 DOI: 10.1016/j.aace.2024.11.002

Kevin S. Wei MD , Alexandra N. Lim MD , Sophie M. Cannon MD

Background/Objective

Thyrotoxic periodic paralysis (TPP) is a rare condition causing weakness of the lower extremities associated with significant hypokalemia. Likewise, agranulocytosis due to methimazole use is a rare occurrence. We present the first documented case of concomitant TPP and agranulocytosis from methimazole use.

Case Report

A 48-year-old woman presented with sore throat, fevers, odynophagia, and sudden-onset bilateral leg weakness. Methimazole had been started 10 weeks prior for a new diagnosis of Graves’ disease. On admission, the patient was febrile, tachycardic, thyrotoxic, and neutropenic. She also experienced near-paralysis of the lower extremities. She was diagnosed with TPP and treated with beta blockade. She was admitted to the intensive care unit and started on broad-spectrum antibiotics, lithium, and propranolol for treatment of septic shock and hyperthyroidism, respectively. Given persistent hypokalemia despite 2 days of therapy, she was also diagnosed with refeeding syndrome.

Discussion

TPP is a rare entity, though it should be considered on the differential for any thyrotoxic patient presenting with sudden weakness. If the associated hypokalemia does not begin to normalize within 48 h of beta blockade, other etiologies should be investigated. Lastly, alternative treatments such as lithium may be used to control hyperthyroidism in patients with methimazole-induced agranulocytosis.

Conclusion

While methimazole-induced agranulocytosis and thyrotoxic periodic paralysis are independently rare diagnoses, the combination of the 2 is exceedingly rare, and our case represents the first documented case in the literature reflecting a patient suffering from both syndromes.

{"title":"A Rare Case of Thyrotoxic Periodic Paralysis in a Patient With Concomitant Methimazole-Induced Agranulocytosis","authors":"Kevin S. Wei MD , Alexandra N. Lim MD , Sophie M. Cannon MD","doi":"10.1016/j.aace.2024.11.002","DOIUrl":"10.1016/j.aace.2024.11.002","url":null,"abstract":"<div><h3>Background/Objective</h3><div>Thyrotoxic periodic paralysis (TPP) is a rare condition causing weakness of the lower extremities associated with significant hypokalemia. Likewise, agranulocytosis due to methimazole use is a rare occurrence. We present the first documented case of concomitant TPP and agranulocytosis from methimazole use.</div></div><div><h3>Case Report</h3><div>A 48-year-old woman presented with sore throat, fevers, odynophagia, and sudden-onset bilateral leg weakness. Methimazole had been started 10 weeks prior for a new diagnosis of Graves’ disease. On admission, the patient was febrile, tachycardic, thyrotoxic, and neutropenic. She also experienced near-paralysis of the lower extremities. She was diagnosed with TPP and treated with beta blockade. She was admitted to the intensive care unit and started on broad-spectrum antibiotics, lithium, and propranolol for treatment of septic shock and hyperthyroidism, respectively. Given persistent hypokalemia despite 2 days of therapy, she was also diagnosed with refeeding syndrome.</div></div><div><h3>Discussion</h3><div>TPP is a rare entity, though it should be considered on the differential for any thyrotoxic patient presenting with sudden weakness. If the associated hypokalemia does not begin to normalize within 48 h of beta blockade, other etiologies should be investigated. Lastly, alternative treatments such as lithium may be used to control hyperthyroidism in patients with methimazole-induced agranulocytosis.</div></div><div><h3>Conclusion</h3><div>While methimazole-induced agranulocytosis and thyrotoxic periodic paralysis are independently rare diagnoses, the combination of the 2 is exceedingly rare, and our case represents the first documented case in the literature reflecting a patient suffering from both syndromes.</div></div>","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"11 1","pages":"Pages 66-69"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial for January/February Issue of AACE Clinical Case Reports

Q3 Medicine

AACE Clinical Case Reports

Pub Date : 2025-01-01 DOI: 10.1016/j.aace.2024.12.008

Sina Jasim MD, MPH (Editor-in-Chief)

引用次数: 0

Hidden in Plain Sight: Incidental Diagnosis of Metastatic Papillary Thyroid Microcarcinoma Without Radiologically Apparent Thyroid Tumor

Q3 Medicine

AACE Clinical Case Reports

Pub Date : 2025-01-01 DOI: 10.1016/j.aace.2024.10.006

Natalie Rivera Vargas MD , Moises Matos MD , Mustafa Kinaan MD, FACE

Background/Objective

Papillary thyroid cancer (PTC) is considered the most common form of thyroid cancer. Papillary thyroid microcarcinomas (PTMCs) are defined as papillary carcinomas that are <1 cm and are often identified on surgical pathology but may be missed by ultrasound imaging.

Case Report

Our case describes a 24-year-old woman who initially presented with a right lateral neck lump. This was thought to be a lipoma, and no workup was performed until it began to grow during pregnancy 3 to 4 years after initial presentation. The patient underwent excision with findings of a level 5B lymph node with pathology consistent with PTC, follicular variant. Neck ultrasound performed in an imaging center and in our clinic did not reveal thyroid nodules or abnormal appearing lymph nodes. Solid tumor profiling assay identified a neurotrophic tropomyosin receptor kinase (NTRK)-3 fusion: ETV6(4)-NTRK3(14) mutation.

Discussion

PTMCs are identified with increased frequency due to improved ultrasound imaging and fine needle aspiration techniques. PTMCs are often associated with a benign course and are rarely metastatic. There has been growing interest in NTRK fusion mutations in PTC that has been associated with an increased risk of metastasis.

Conclusion

This case is unusual in that multiple cervical nodal metastases were present even without a sizable primary thyroid tumor. Although more studies are needed to elucidate the clinical and prognostic significance of NTRK fusion mutations in PTMC, their response to tropomyosin receptor kinase inhibitors may represent a future pathway for treatment.

{"title":"Hidden in Plain Sight: Incidental Diagnosis of Metastatic Papillary Thyroid Microcarcinoma Without Radiologically Apparent Thyroid Tumor","authors":"Natalie Rivera Vargas MD , Moises Matos MD , Mustafa Kinaan MD, FACE","doi":"10.1016/j.aace.2024.10.006","DOIUrl":"10.1016/j.aace.2024.10.006","url":null,"abstract":"<div><h3>Background/Objective</h3><div>Papillary thyroid cancer (PTC) is considered the most common form of thyroid cancer. Papillary thyroid microcarcinomas (PTMCs) are defined as papillary carcinomas that are <1 cm and are often identified on surgical pathology but may be missed by ultrasound imaging.</div></div><div><h3>Case Report</h3><div>Our case describes a 24-year-old woman who initially presented with a right lateral neck lump. This was thought to be a lipoma, and no workup was performed until it began to grow during pregnancy 3 to 4 years after initial presentation. The patient underwent excision with findings of a level 5B lymph node with pathology consistent with PTC, follicular variant. Neck ultrasound performed in an imaging center and in our clinic did not reveal thyroid nodules or abnormal appearing lymph nodes. Solid tumor profiling assay identified a neurotrophic tropomyosin receptor kinase (NTRK)-3 fusion: ETV6(4)-NTRK3(14) mutation.</div></div><div><h3>Discussion</h3><div>PTMCs are identified with increased frequency due to improved ultrasound imaging and fine needle aspiration techniques. PTMCs are often associated with a benign course and are rarely metastatic. There has been growing interest in NTRK fusion mutations in PTC that has been associated with an increased risk of metastasis.</div></div><div><h3>Conclusion</h3><div>This case is unusual in that multiple cervical nodal metastases were present even without a sizable primary thyroid tumor. Although more studies are needed to elucidate the clinical and prognostic significance of NTRK fusion mutations in PTMC, their response to tropomyosin receptor kinase inhibitors may represent a future pathway for treatment.</div></div>","PeriodicalId":7051,"journal":{"name":"AACE Clinical Case Reports","volume":"11 1","pages":"Pages 58-61"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reviewer Acknowledgment 2024

Q3 Medicine

AACE Clinical Case Reports

Pub Date : 2025-01-01 DOI: 10.1016/j.aace.2024.12.009

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

AACE Clinical Case Reports

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀